ATE556710T1 - Verbesserung der durch ampakine induzierten erleichterung von synaptischen reaktionen durch cholinesterase-inhibitoren - Google Patents

Verbesserung der durch ampakine induzierten erleichterung von synaptischen reaktionen durch cholinesterase-inhibitoren

Info

Publication number
ATE556710T1
ATE556710T1 AT05712023T AT05712023T ATE556710T1 AT E556710 T1 ATE556710 T1 AT E556710T1 AT 05712023 T AT05712023 T AT 05712023T AT 05712023 T AT05712023 T AT 05712023T AT E556710 T1 ATE556710 T1 AT E556710T1
Authority
AT
Austria
Prior art keywords
ampakine
synaptic
reactions
improvement
cholinesterase inhibitors
Prior art date
Application number
AT05712023T
Other languages
English (en)
Inventor
Ursula Staubli
Gary Lynch
Sheng Zhong
Laura Colgin
Original Assignee
Cortex Pharma Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortex Pharma Inc, Univ California filed Critical Cortex Pharma Inc
Application granted granted Critical
Publication of ATE556710T1 publication Critical patent/ATE556710T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05712023T 2004-01-26 2005-01-26 Verbesserung der durch ampakine induzierten erleichterung von synaptischen reaktionen durch cholinesterase-inhibitoren ATE556710T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53942204P 2004-01-26 2004-01-26
PCT/US2005/002372 WO2005072345A2 (en) 2004-01-26 2005-01-26 Enhancement of ampakine-induced facilitation of synaptic responses by cholinesterase inhibitors

Publications (1)

Publication Number Publication Date
ATE556710T1 true ATE556710T1 (de) 2012-05-15

Family

ID=34826078

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05712023T ATE556710T1 (de) 2004-01-26 2005-01-26 Verbesserung der durch ampakine induzierten erleichterung von synaptischen reaktionen durch cholinesterase-inhibitoren

Country Status (7)

Country Link
US (1) US20050228019A1 (de)
EP (1) EP1715863B1 (de)
JP (1) JP2007519733A (de)
AT (1) ATE556710T1 (de)
AU (1) AU2005208871B2 (de)
CA (1) CA2554600A1 (de)
WO (1) WO2005072345A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL378366A1 (pl) * 2003-01-13 2006-04-03 Cortex Pharmaceuticals, Inc. Sposób leczenia osłabienia funkcji poznawczych spowodowanego deprywacją snu i stresem
US20080139472A1 (en) * 2006-10-06 2008-06-12 The Regents Of The University Of California Upregulating bdnf levels to mitigate mental retardation
CA2680920A1 (en) * 2007-03-23 2008-10-02 The Regents Of The University Of California Treatment of female sexual dysfunction by compounds that positively modulate ampa-type glutamate receptors
US20110053859A1 (en) * 2007-10-10 2011-03-03 The U. S. Government Respresented by the Department of Veterans Affairs Methods to reduce the effects of sleep deprivation
FR2931677B1 (fr) * 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
PT105083A (pt) 2009-04-28 2011-07-25 Univ De Coimbra Processo para cultura de células estaminais neurais baseado nas ampacinas e/ou outros moduladores de receptores glutamatérgicos ionotrópicos, composições e seu uso em condições do sistema nervoso central
WO2012121971A2 (en) 2011-03-04 2012-09-13 The Regents Of The University Of California Locally released growth factors to mediate motor recovery after stroke
FR3019464B1 (fr) * 2014-04-07 2016-05-06 Servier Lab Nouvelle association entre le 8-cyclopropyl-3-[2-(3-fluorophenyl)ethyl]-7,8-dihydro-3h-[1,3]oxazino[6,5-g] [1,2,3]benzotriazine-4,9-dione et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
WO2018009256A1 (en) * 2016-03-29 2018-01-11 Respirerx Pharmaceuticals, Inc. Compositions and methods for treating attention deficit disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306825A (en) * 1984-03-01 1994-04-26 Consiglio Nazionale Delle Ricerche Physostigmine derivatives with acetylcholinesterase inhibition properties, and the relative production process
US4647580A (en) * 1985-07-18 1987-03-03 Syntex (U.S.A.) Inc. Treatment of Alzheimer's disease
ES2210060T3 (es) * 1992-07-24 2004-07-01 The Regents Of The University Of California Farmacos que aumentan las respuestas sinapticas mediadas por receptores ampa.
US6274600B1 (en) * 1995-06-05 2001-08-14 The Regents Of The University Of California Heteroatom substituted benzoyl derivatives that enhance synaptic responses mediated by AMPA receptors
US5773434A (en) * 1995-08-30 1998-06-30 Gary A. Rogers Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia
US5665880A (en) * 1996-10-31 1997-09-09 Hoechst Marion Roussel, Inc. Method of preparation of physostigmine carbamate derivatives from eseretholes
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
BR9814106A (pt) * 1997-10-27 2000-10-03 Cortex Pharma Inc Processo para tratar da esquizofrenia em um indivìduo, e, conjunto
IL125809A (en) * 1998-08-17 2005-08-31 Finetech Lab Ltd Process and intermediates for production of donepezil and related compounds
DE60124730T2 (de) * 2000-03-03 2007-10-04 Eisai R&D Management Co., Ltd. Neue methoden unter verwendung von cholinesteraseinhibitoren
EP1203584A1 (de) * 2000-10-13 2002-05-08 M.D.M. S.r.l. Cholinerger Vorläufer (insbesondere Cholin-alfoscerat) assoziiert mit einem Acetylcholinesterase Inhibitor (wie z.B. Rivastigmin, Donepezil)

Also Published As

Publication number Publication date
JP2007519733A (ja) 2007-07-19
EP1715863B1 (de) 2012-05-09
EP1715863A4 (de) 2009-03-25
CA2554600A1 (en) 2005-08-11
AU2005208871A1 (en) 2005-08-11
WO2005072345A2 (en) 2005-08-11
AU2005208871B2 (en) 2010-04-01
WO2005072345A3 (en) 2005-12-22
US20050228019A1 (en) 2005-10-13
EP1715863A2 (de) 2006-11-02

Similar Documents

Publication Publication Date Title
ATE556710T1 (de) Verbesserung der durch ampakine induzierten erleichterung von synaptischen reaktionen durch cholinesterase-inhibitoren
CY1120922T1 (el) Παραγωγα πυρρολιου ως φαρμακευτικοι παραγοντες
ATE421512T1 (de) Inhibitoren von mitotischem kinesin
ATE356804T1 (de) Inhibitoren von mitotischem kinesin
ATE446094T1 (de) Mitotische kinesin-hemmer
ATE448207T1 (de) Mitotische kinesin-hemmer
ATE372341T1 (de) Inhibitoren von mitotischem kinesin
ATE447577T1 (de) Mitotische kinesin-hemmer
WO2006018024A3 (en) Cosmetic and pharmaceutical compositions comprising ace inhibitors and/or angiotensin ii receptor antagonists
BRPI0517418A (pt) composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
BRPI0511139B8 (pt) compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
TW200634006A (en) Tetrahydroquinoline analogues as muscarinic agonists
WO2008036846A3 (en) Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
WO2004058148A3 (en) Mitotic kinesin inhibitors
WO2004058700A3 (en) Mitotic kinesin inhibitors
MXPA05007379A (es) Metodo para tratar nauseas, vomito, esfuerzo por vomitar o cualquier combinacion de los mismos.
TW200605871A (en) Carboxamido opioid compounds
UA94922C2 (ru) Способ регулирования специфичности сигнализации тканевого фактора у млекопитающего, которое нуждается в этом, способ идентификации агента, который специфически ингибирует сигнализацию тканевого фактора
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
WO2004062623A3 (en) Method of treating functional bowel disorders
DE602006008583D1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
ATE478661T1 (de) Verfahren zur reduzierung der angiogenese
ATE482218T1 (de) Inhibitoren von mitotischem kinesin